370 related articles for article (PubMed ID: 22198747)
1. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
Wu C; Dunbar CE
Front Med; 2011 Dec; 5(4):356-71. PubMed ID: 22198747
[TBL] [Abstract][Full Text] [Related]
2. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
Trobridge GD
Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for PIDs: progress, pitfalls and prospects.
Mukherjee S; Thrasher AJ
Gene; 2013 Aug; 525(2):174-81. PubMed ID: 23566838
[TBL] [Abstract][Full Text] [Related]
4. Ten years of gene therapy for primary immune deficiencies.
Aiuti A; Roncarolo MG
Hematology Am Soc Hematol Educ Program; 2009; ():682-9. PubMed ID: 20008254
[TBL] [Abstract][Full Text] [Related]
5. Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials.
Baum C
EMBO Mol Med; 2011 Feb; 3(2):75-7. PubMed ID: 21254403
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy Approaches to Immunodeficiency.
Ghosh S; Gaspar HB
Hematol Oncol Clin North Am; 2017 Oct; 31(5):823-834. PubMed ID: 28895850
[TBL] [Abstract][Full Text] [Related]
8. Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning.
Schwarzer A; Talbot SR; Selich A; Morgan M; Schott JW; Dittrich-Breiholz O; Bastone AL; Weigel B; Ha TC; Dziadek V; Gijsbers R; Thrasher AJ; Staal FJT; Gaspar HB; Modlich U; Schambach A; Rothe M
Mol Ther; 2021 Dec; 29(12):3383-3397. PubMed ID: 34174440
[TBL] [Abstract][Full Text] [Related]
9. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
[TBL] [Abstract][Full Text] [Related]
10. A possible turning point in the hematopoietic stem cell gene therapy for primary immunodeficiency diseases? Lentiviral vectors could take the place of retroviral vectors.
Ariga T
Expert Rev Clin Immunol; 2013 Nov; 9(11):1015-8. PubMed ID: 24168409
[TBL] [Abstract][Full Text] [Related]
11. Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable.
von Kalle C; Fehse B; Layh-Schmitt G; Schmidt M; Kelly P; Baum C
Semin Hematol; 2004 Oct; 41(4):303-18. PubMed ID: 15508116
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for severe combined immunodeficiencies and beyond.
Fischer A; Hacein-Bey-Abina S
J Exp Med; 2020 Jan; 217(2):. PubMed ID: 31826240
[TBL] [Abstract][Full Text] [Related]
13. Concise review: managing genotoxicity in the therapeutic modification of stem cells.
Baum C; Modlich U; Göhring G; Schlegelberger B
Stem Cells; 2011 Oct; 29(10):1479-84. PubMed ID: 21898683
[TBL] [Abstract][Full Text] [Related]
14. Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a⁻/⁻ mice.
Montini E; Cesana D
Methods Enzymol; 2012; 507():171-85. PubMed ID: 22365774
[TBL] [Abstract][Full Text] [Related]
15. Gene Therapies for Primary Immune Deficiencies.
Kohn LA; Kohn DB
Front Immunol; 2021; 12():648951. PubMed ID: 33717203
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for inherited immunodeficiency.
Touzot F; Hacein-Bey-Abina S; Fischer A; Cavazzana M
Expert Opin Biol Ther; 2014 Jun; 14(6):789-98. PubMed ID: 24823313
[TBL] [Abstract][Full Text] [Related]
17. The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy.
Métais JY; Dunbar CE
Mol Ther; 2008 Mar; 16(3):439-49. PubMed ID: 18227842
[TBL] [Abstract][Full Text] [Related]
18. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
[TBL] [Abstract][Full Text] [Related]
19. Clinical applications of gene therapy for primary immunodeficiencies.
Cicalese MP; Aiuti A
Hum Gene Ther; 2015 Apr; 26(4):210-9. PubMed ID: 25860576
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
